Department of Thoracic Surgery, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Statistics Center, Shanghai Chest Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
J Thorac Oncol. 2023 May;18(5):640-649. doi: 10.1016/j.jtho.2022.12.013. Epub 2023 Jan 13.
Increasing evidence supports minimally invasive thymectomy (MIT) for early stage thymic malignancies than open median sternotomy thymectomy (MST). Nevertheless, whether MIT could be attempted for locally advanced disease remains unclear.
The clinical data of consecutive patients with stage T2-3NxM0 (eighth edition TNM staging) thymic malignancies who underwent MIT or MST were identified from a prospectively maintained database. The co-resected structures were rated with a resection index to evaluate surgical difficulty. The impact of surgical approach on treatment outcomes was investigated through propensity score-matched analysis and multivariable analysis.
From January 2008 to December 2019, a total of 128 patients were included; MIT was initially attempted in 58 (45.3%) cases, and eight (13.8%) were converted to MST during surgery. The conversion group had similar perioperative outcomes to the MST group, except for a longer operation time. After propensity score matching, the resection index scores were similar between the MIT and MST groups (3.5 versus 3.7, p = 0.773). The MIT group had considerably less blood loss (p < 0.001), fewer postoperative complications (p = 0.048), a shorter duration of chest drainage (p < 0.001), and a shorter hospitalization duration (p < 0.001) than the MST group. The 5-year freedom from recurrence rate was not different between the two groups (78.2% versus 78.5%, p = 0.942). In multivariable analysis, surgical approach was not associated with freedom from recurrence (p = 0.727).
MIT could be safely attempted in carefully selected patients with locally advanced thymic tumors. Conversion did not compromise the surgical outcomes. Patients may benefit from the less traumatic procedure and thus better recovery, with comparable long-term oncologic outcomes.
越来越多的证据支持对早期胸腺恶性肿瘤采用微创胸腺切除术(MIT),而不是正中开胸胸腺切除术(MST)。然而,对于局部晚期疾病是否可以尝试 MIT 尚不清楚。
从一个前瞻性维护的数据库中,确定了连续接受 MIT 或 MST 治疗的分期为 T2-3NxM0(第八版 TNM 分期)胸腺恶性肿瘤患者的临床资料。采用切除指数对共同切除的结构进行评分,以评估手术难度。通过倾向评分匹配分析和多变量分析,研究手术方法对治疗结果的影响。
2008 年 1 月至 2019 年 12 月,共纳入 128 例患者;58 例(45.3%)患者最初尝试 MIT,8 例(13.8%)患者在手术中转为 MST。转换组的围手术期结果与 MST 组相似,除了手术时间较长外。经过倾向评分匹配后,MIT 组和 MST 组的切除指数评分相似(3.5 比 3.7,p=0.773)。MIT 组的出血量明显减少(p<0.001),术后并发症更少(p=0.048),胸腔引流时间更短(p<0.001),住院时间更短(p<0.001)。两组 5 年无复发生存率无差异(78.2%比 78.5%,p=0.942)。多变量分析显示,手术方法与无复发生存无关(p=0.727)。
在仔细选择的局部晚期胸腺瘤患者中,可以安全地尝试 MIT。转换不会影响手术结果。患者可能会从创伤较小的手术中获益,从而更好地恢复,并且具有相似的长期肿瘤学结果。